24.02.2015 • NewsDede WillamsSanofiLead Pharma

Sanofi and Lead Pharma Seal Autoimmune R&D Pact

French drugmaker Sanofi and Dutch biotech Lead Pharma have entered a research collaboration and license agreement to discover, develop and commercialize small-molecule therapies directed against nuclear hormone receptors known as ROR gamma t.

Under the terms of the agreement, the two companies will collaborate during the early phase of research and development with a goal of identifying drug candidates and beginning human trials within 3-4 years.

Lead Pharma will receive an upfront payment and is eligible to receive research, development, regulatory and commercial milestone payments. Sanofi will be responsible for clinical development and have worldwide marketing and commercialization rights to any products that may be developed as a result of the collaboration. Lead Pharma is entitled to receive royalty payments on global sales from any such products. Further details of the financial terms have not been disclosed.

These drugs are aimed at treating a broad range of autoimmune disorders, including rheumatoid arthritis, psoriasis and inflammatory bowel disease.

"Anti-ROR gamma t therapies represent a groundbreaking opportunity that we are eager and motivated to pursue through our collaboration with Lead Pharma," said Christian Antoni, vice president and head of the Immunology & Inflammation Franchise, Research & Development at the French company. "At Sanofi, we believe networked innovations - working collaboratively across science sectors - is the most effective way to bring meaningful new therapies to patients," he said.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.

Photo
24.01.2025 • News

And the Winners are: Cynio, EnaDyne and Green Li-ion

The CHEManager Innovation Pitch, the start-up promotion initiative of CHEManager and CHEManager International, has given more than 100 start-ups from over 15 countries the opportunity to present their innovative ideas, products and technologies to a broad target group since its launch in 2019.

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.